Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05169177
Other study ID # IX-2020-DS-ROCKRT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 17, 2022
Est. completion date October 31, 2026

Study information

Verified date June 2023
Source University of Sydney
Contact Shona Silvester
Phone +61 2 8627 1185
Email Shona.Silvester@sydney.edu.au
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).


Description:

- Sites will collect image files from the Cancer Radiation Therapy Systems and the medical records of eligible participants. For patient who do not have implanted markers, research personnel (a radiation oncologist, medical physicist or radiation therapist) will manually outline the visible contrast mass. This outline is considered the 'ground truth' of the location of the contrast mass. To ensure its accuracy, the ground truth contrast mass location will be checked by research personnel from another study site. - Image and ground truth data collected from 80% of participants will be used by University of Sydney researchers to develop the KIM algorithm to detect and track the radio-opaque contrast agents with sufficient robustness to provide justification for the prospective use of KIM as a real-time image guided radiation therapy tool for liver cancer patients. - The developed KIM software will be applied by site Medical Physicist(s) to the treatment imaging data from the remaining 20% of participants the images. Tumour positions produced by KIM will be compared with a 'ground truth' manual delineation.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 31, 2026
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site. - Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan - The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking. - Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited) Exclusion Criteria: - Less than 18 years of age - Minimum image dataset is not available - Image dataset is not in a compatible format

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Australia Peter MacCallum Cancer Centre Melbourne Victoria
Australia The Austin Hospital Melbourne Victoria
Australia Calvary Mater Newcastle Hospital Waratah New South Wales
Australia Westmead Hospital Westmead New South Wales
Australia Princess Alexandra Hospital Woolloongabba Queensland

Sponsors (6)

Lead Sponsor Collaborator
University of Sydney Austin Health, Calvary Mater Newcastle, Australia, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia, Western Sydney Local Health District

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of images that have contrast mass detection by software Proportion of images in which kilovoltage intrafraction monitoring software detects contrast agent mass on CBCT and intra-treatment images 2 weeks
Primary Average difference between software and ground truth measure Average difference (mm) of location of contrast mass detection on CBCT and treatment images by KIM software compared to the ground truth in each of the horizontal and vertical directions. 2 weeks
Primary Standard deviation of difference between software and ground truth measure Standard deviation difference (mm) of location of contrast mass detection on CBCT and treatment images by KIM software compared to the ground truth in each of the horizontal and vertical directions. 2 weeks
Secondary Modelling of patient or treatment features that contributed to the success or failure of the KIM method Using the KIM success rate (primary hypothesis) and patient CT imaging features (contrast agent density, size, shape and location, patient size etc) a generalised linear model, or appropriate alternative, will be used to identity univariate and multivariate patient or treatment features that contributed to the success or failure of the KIM method. Selected features will be identified and developed into a model. If the model predicts the likelihood of KIM success in at least 85% of the patients then the study will be deemed to have achieved the hypothesis. 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Terminated NCT04702230 - Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
Active, not recruiting NCT01217034 - Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib Phase 2
Withdrawn NCT02599909 - Gut Microbiota in People With Hepatocellular Carcinoma (HCC)
Terminated NCT03998033 - Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Phase 1
Recruiting NCT04010071 - Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors Phase 2
Recruiting NCT04864054 - T-Cell Therapy (ECT204) in Adults With Advanced HCC Phase 2
Terminated NCT04187937 - Feasibility of Ultrasound-based Navigation for Non-anatomical Liver Resections N/A
Completed NCT02471313 - Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization Phase 2
Completed NCT00001576 - A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver Phase 1
Recruiting NCT01542281 - Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer N/A
Recruiting NCT03803436 - Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation Phase 2
Completed NCT05495529 - Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
Recruiting NCT02632864 - Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial Phase 2
Completed NCT02571946 - Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis N/A
Not yet recruiting NCT01180088 - Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy N/A
Withdrawn NCT00510627 - Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases Phase 4
Completed NCT05848947 - SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA Phase 4
Not yet recruiting NCT05723705 - Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
Terminated NCT04502082 - Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) Phase 1/Phase 2